We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Native Antigens to Improve Diagnostic Testing for Human Metapneumovirus
Product News

Native Antigens to Improve Diagnostic Testing for Human Metapneumovirus

Native Antigens to Improve Diagnostic Testing for Human Metapneumovirus
Product News

Native Antigens to Improve Diagnostic Testing for Human Metapneumovirus


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Native Antigens to Improve Diagnostic Testing for Human Metapneumovirus"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

 First isolated in 2001, hMPV in an important cause of community-acquired acute respiratory infection.  Serious illness may occur in the very young and in those who are chronically ill or immunosuppressed. The identification of hMPV infection has predominantly relied on real-time PCR which can be time consuming and costly.  The availability of this native antigen provides the in-vitro diagnostic manufacturer with the opportunity to develop cost effective test kits based  upon rapid lateral flow and ELISA formats.

Dr Nick Roesen, NAC’s Scientific Director said ““Our hMPV A and B native antigens are identical to the virus itself as it appears in the patient and this means that IVD manufacturers can now develop rapid tests which offer the highest levels of sensitivity and specificity to the infection.”

Advertisement